ArticleAnimals : an open access journal from MDPI2025
Inactivated Type 'O' Foot and Mouth Disease Virus Encapsulated in Chitosan Nanoparticles Induced Protective Immune Response in Guinea Pigs.
Article in Animals : an open access journal from MDPI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot and mouth disease is a contagious viral disease infecting ungulates, with great economic impact on farmers' income; it is primarily controlled using inactivated vaccines, which have certain limitations, such as short-lived immunity and a lack of mucosal immunity at the portals of virus entry. The present approach aims to exploit the efficiency of chitosan nanoparticle-encapsulated inactivated type 'O' FMDV antigen (FMDV-CS-NPs) to induce mucosal and systemic immune responses in a guinea pig animal model through intranasal and intramuscular administration in comparison with the conventional inactivated, mineral oil-adjuvanted vaccine that is administered systemically. In this study, the FMDV-CS-NPs were prepared by ionotropic gelation, followed by incubation; were characterized for their physical properties and in vitro antigen release; and were found to encapsulate a good amount of antigen. The prepared nanoparticles were assessed for their ability to induce humoral and cell-mediated immune responses by SNTs; indirect ELISAs for serum IgG, IgG1, and IgG2; and nasal washing sIgA and lymphocyte proliferation assays. The preparation induced comparatively more measurable sIgA and systemic immune responses with the intranasal and intramuscular routes of administration, respectively, which are attributable to a specific interaction between the positively charged chitosan and the negatively charged mucosal surface and cell membrane. The challenge infection protected 87.5% of the animals in the FMDV-CS-NP I/M group, followed by 77.7% in the FMDV-CS-NP I/N and inactivated vaccine groups. The outcomes of this study in guinea pigs highlight that chitosan nanoparticle-based vaccine formulations could be employed as a promising antigen delivery system for targeted delivery, devoid of any adverse effect, to induce protective immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.